Bio-Thera Solutions Ltd. (688177)

Overview

Founded in 2003 and based in Guangzhou, China, Bio-Thera Solutions, Ltd. stands as a pioneering biopharmaceutical entity engaged in the discovery, development, and delivery of innovative therapeutics. The company's research focuses on addressing the unmet needs in the treatment of cancer, autoimmune, cardiovascular, and other severe medical conditions on both national and international fronts. Through its commitment to innovation, Bio-Thera Solutions, Ltd. strives to enhance patient care and provide novel treatment options for several serious health issues.

Products and Services

• QLETLI

  Designed to combat a range of autoimmune diseases, QLETLI is approved for treating conditions such as ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis, offering those afflicted new hope and respite from their symptoms.

• POBEVCY

  POBEVCY marks a significant advancement in oncology, particularly for patients battling metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, and metastatic cervical cancer, by presenting an alternative therapeutic option.

• BAT1806

  This treatment is geared towards addressing the needs of patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome, highlighting the company's commitment to tackling a wide range of autoimmune and inflammatory conditions.

• BAT2206

  A biosimilar candidate that targets a variety of conditions such as psoriasis, Crohn's disease, and ulcerative colitis. BAT2206 exemplifies the company's efforts in extending accessible treatment options for chronic and debilitating disorders.

• BAT2306

  Encompassing treatments for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, BAT2306 is another testament to the firm's dedication to advancing care for autoimmune diseases.

• Other Developmental Drugs

  Bio-Thera Solutions, Ltd. is also working on several other promising drugs, including BAT4406F, BAT6026, BAT2606, and BAT2506 for autoimmune diseases; BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for oncology; BAT2094 and BAT6024 for cardiovascular diseases; and BAT5906 which is in Phase III clinical trials for wet age-related macular degeneration (wAMD) and Phase II clinical trials for diabetic macular edema (DME); plus BAT2022 for respiratory infectious diseases. This diversification underscores a robust pipeline aimed at addressing a broad spectrum of serious health conditions with innovative therapeutic solutions.